Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Fudan University
Medpace, Inc.
Information provided by (Responsible Party):
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01489566
First received: December 1, 2011
Last updated: December 13, 2011
Last verified: December 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is enrolling participants by invitation only.
  Estimated Study Completion Date: August 2013
  Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)